Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.46 |
| ▸ | AHR | P35869 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5460356 | 0.95 | LOXL2 (0.56) | LOXL2HRH3MTNR1AMTNR1BCHRNA7 | |
| SCHEMBL153397 | 0.87 | LOXL2 (0.60) | LOXL2HRH3MTNR1AMTNR1BCHRNA7 | |
| SCHEMBL6860219 | 0.87 | LOXL2 (0.64) | LOXL2HRH3MTNR1AMTNR1BCHRNA7 | |
| SCHEMBL31059889 | 0.82 | LOXL2 (0.69) | LOXL2HRH3MTNR1AMTNR1BCHRNA7 | |
| SCHEMBL7169246 | 0.82 | LOXL2 (0.69) | LOXL2HRH3MTNR1AMTNR1BCHRNA7 | |
| SCHEMBL30382957 | 0.82 | CTSV (0.60) | LOXL2HRH3MTNR1AMTNR1BCHRNA7 | |
| SCHEMBL14386719 | 0.82 | LOXL2 (0.55) | LOXL2HRH3MTNR1AMTNR1BCHRNA7 | |
| SCHEMBL28235854 | 0.82 | LOXL2 (0.55) | LOXL2HRH3MTNR1AMTNR1BCHRNA7 | |
| SCHEMBL8376332 | 0.82 | LOXL2 (0.65) | LOXL2HRH3MTNR1AMTNR1BCHRNA7 | |
| SCHEMBL369110 | 0.82 | CTSV (0.60) | LOXL2HRH3MTNR1AMTNR1BCHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | NOVARTIS AG (CH) | 2007-02-22 | — | — | US | claimed |
| EP-1615898-A1 | 2-AMINOPYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE | Novartis AG (CH) | 2006-01-18 | — | — | EP | claimed |
| WO-2004089913-A1 | AMINOPYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE | NOVARTIS AG (CH) | 2004-10-21 | — | — | WO | claimed |
| WO-2015044928-A1 | SUBSTITUTED INDOLES AND THEIR USE AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | STELLENBOSCH UNIVERSITY (ZA) | 2015-04-02 | — | — | WO | disclosed |
| WO-2010134939-A2 | MAMMALIAN GENES INVOLVED IN INFECTION | Zirus, Inc. (US) | 2010-11-25 | — | — | WO | disclosed |
| US-7615562-B2 | Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents | NOVARTIS AG (CH) | 2009-11-10 | — | — | US | disclosed |
| US-7601751-B2 | Indole acetic acid acyl guanidines as β-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090131494-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | MERCK SHARP & DOHME CORP. | 2009-05-21 | — | — | US | disclosed |
| EP-1915055-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Merck & Co., Inc. (US) | 2008-04-30 | — | — | EP | disclosed |
| US-20070049589-A1 | Indole acetic acid acyl guanidines as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-01 | — | — | US | disclosed |
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | NOVARTIS AG (CH) | 2007-02-22 | — | — | US | disclosed |
| WO-2007021629-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2006041961-A1 | ARYLTHIOINDOLE TUBULIN POLYMERIZATION INHIBITORS AND METHODS OF TREATING OR PREVENTING CANCER USING SAME | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTHAND HUMAN SERVICES (US) | 2006-04-20 | — | — | WO | disclosed |
| EP-1615898-A1 | 2-AMINOPYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE | Novartis AG (CH) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004089913-A1 | AMINOPYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE | NOVARTIS AG (CH) | 2004-10-21 | — | — | WO | disclosed |
| WO-2003027089-A1 | BENZOFURAN, INDOLE OR BENZOTHIOPHENE 2,4-PENTADIENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS | ALLERGAN, INC. (US) | 2003-04-03 | — | — | WO | disclosed |
| US-6388105-B1 | ANTIPROLIFERATIVE AGENTS; SKIN DISORDERS; ANTIINFLAMMATORY AGENTS | ALLERGAN SALES, INC. | 2002-05-14 | — | — | US | disclosed |
| US-5459142-A | Autoimmune disease, atherosclerosis, antiischemic agents and nephritis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-10-17 | — | — | US | disclosed |
| EP-0511879-B1 | Pyrazine derivatives | OTSUKA PHARMA CO LTD (JP) | 1995-03-22 | — | — | EP | disclosed |
| EP-0511879-A1 | Pyrazine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | TPMT, IKBKB, CHUK | LOXL2 3664/4885HRH3 4406/4885MTNR1A 4110/4885 |
| US-20070049589-A1 | Indole acetic acid acyl guanidines as beta-secretase inhibitors | BACE1, APP, BACE2 | LOXL2 4745/4885HRH3 506/4885MTNR1A 1114/4885 |
| US-20090131494-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | IDO1, IDO2, INMT | LOXL2 4287/4885HRH3 1542/4885MTNR1A 2188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.